Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis

Aliment Pharmacol Ther. 2007 Apr 15;25(8):933-9. doi: 10.1111/j.1365-2036.2007.03291.x.

Abstract

Aim: To determine if small bowel involvement at diagnosis could predict early relapse in children with ulcerative colitis.

Methods: Children with newly diagnosed ulcerative colitis were evaluated prospectively at three time points: within 1 month, 6 months and 1 year after diagnosis. Clinical activity indices were used to measure disease activity. Laboratory studies were performed at each visit and/or at the time of relapse. At diagnosis, all patients underwent colonoscopy and a cellobiose/mannitol small intestinal permeability study. Some children were further investigated with an upper gastrointestinal endoscopy.

Results: Thirty-three patients completed the 1-year study. Overall, nine patients (27.3%) relapsed within 6 months of diagnosis, one patient (3%) within 1 year, whereas 23 patients (69.7%) did not relapse. The mean clinical activity indices, laboratory parameters, extent of colonic involvement, upper and lower gastrointestinal histological features were not predictive of early relapse. Results of the cellobiose/mannitol small intestinal permeability study were significantly higher in children who relapsed within 6 months compared with children who did not relapse (P < 0.013). The cellobiose/mannitol small intestinal permeability study was abnormal in 77.8% of early relapsers compared with only 8.3% of non-relapsers.

Conclusion: Abnormal small intestinal permeability in children with ulcerative colitis could predict a more relapsing disease.

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Antineutrophil Cytoplasmic / metabolism
  • Cellobiose / pharmacokinetics
  • Child
  • Child, Preschool
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / metabolism
  • Colitis, Ulcerative / pathology
  • Diuretics, Osmotic / pharmacokinetics
  • Female
  • Humans
  • Infant
  • Intestine, Small / metabolism
  • Intestine, Small / pathology*
  • Male
  • Mannitol / pharmacokinetics
  • Mesalamine / therapeutic use
  • Methylprednisolone / therapeutic use
  • Permeability / drug effects
  • Predictive Value of Tests
  • Prospective Studies
  • Secondary Prevention

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Antineutrophil Cytoplasmic
  • Diuretics, Osmotic
  • Cellobiose
  • Mannitol
  • Mesalamine
  • Methylprednisolone